In patients with primary aldosteronism, treatment through pharmacological MR antagonists (MRA) (eplerenone or spironolactone) or adrenalectomy reduces visceral fat mass [46] and improves systemic and organ insulin sensitivity [47], but other studies have shown only limited effects of MRA in obese diabetic patients [48,49,50]. The gene discussed is INS; the disease is primary aldosteronism.